About: Clinical Features of COVID‐19‐Infected Patients With Elevated Liver Biochemistries: A Multicenter, Retrospective Study

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Clinical Features of COVID‐19‐Infected Patients With Elevated Liver Biochemistries: A Multicenter, Retrospective Study Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Clinical Features of COVID‐19‐Infected Patients With Elevated Liver Biochemistries: A Multicenter, Retrospective Study
Creator	Zhang, Ying Fu, Yu Zhu, Rui Yi, Jianhua Bai, Tao He, Qin Chen, Chaoyue Yan, Wei Tian, Dean Han, Ping Jing, Mengjia Quan, Runze Tao, Meihui Xiong, Xiaofeng Zhao, Xi
Source	Medline; PMC
abstract	In December 2019, an outbreak of coronavirus disease 2019 (COVID‐19) emerged in Wuhan, China. Although it has been reported that some COVID‐19 patients showed elevated liver biochemistries, there are few studies regarding clinical features and prognosis of these patients. In this multicenter, retrospective study, we collected data on laboratory‐confirmed COVID‐19 patients from three hospitals in Wuhan, China, who died or were discharged between February 1, 2020, and February 20, 2020. The data on demographics, comorbidities, clinical symptoms, laboratory examinations on admission, complications, treatment, and outcome were collected. A total of 482 patients were enrolled in this study. Of those, 142 (29.5%) patients showed abnormal liver biochemistries on admission, and patients with elevated alanine aminotransferase (ALT), aspartate aminotransferase (AST), and total bilirubin (TBIL) accounted for 67.6%, 69.0%, and 16.2%, respectively. Those with abnormal liver biochemistries showed higher percentages of severe cases and comorbidities and were more likely to have dyspnea, chest distress or pain, and increased hemoglobin (Hb) on admission. Higher rates of complications and mortality and worse recovery when discharged were observed in patients with abnormal AST or TBIL. The multivariable regression analysis showed that chest distress or pain (odds ratio [OR], 1.765; P = 0.018), dyspnea (OR, 2.495; P = 0.001), elevated C‐reactive protein [CRP] level (OR, 1.007; P = 0.008), elevated white blood count (WBC) (OR, 1.139; P = 0.013), and elevated Hb concentration (OR, 1.024; P = 0.001) were independent factors associated with elevated liver biochemistries in COVID‐19 patients. Conclusion: Elevated liver biochemistries were common in COVID‐19 patients. Patients with hypoxia or severe inflammation are more likely to experience increased liver biochemistries on admission. Those with abnormal AST or TBIL on admission are more likely to suffer from severe complications and death.
has issue date	2020-06-30(xsd:dateTime)
bibo:doi	10.1002/hep.31446
bibo:pmid	32602604
has license	no-cc
sha1sum (hex)	817e5187cdd7411a9e9f2f7ff11483ec0f4d16ac
schema:url	https://doi.org/10.1002/hep.31446
resource representing a document's title	Clinical Features of COVID‐19‐Infected Patients With Elevated Liver Biochemistries: A Multicenter, Retrospective Study
has PubMed Central identifier	PMC7361581
has PubMed identifier	32602604
schema:publication	Hepatology
resource representing a document's body	covid:817e5187cdd7411a9e9f2f7ff11483ec0f4d16ac#body_text
is schema:about of	named entity 'Liver' named entity 'Study' named entity 'Liver' named entity 'red blood cells' named entity 'liver' named entity 'SARS-COV-2' named entity 'leukocytes' named entity 'COVID-19' named entity 'membrane permeability' named entity 'TBIL' named entity 'liver' named entity 'liver' named entity 'liver injury' named entity 'liver' named entity 'comorbidity' named entity 'liver' named entity 'CRP' named entity 'AST' named entity 'lymphocyte count' named entity 'inflammatory response' named entity 'ATP' named entity 'creatinine' named entity 'liver' named entity 'LDH' named entity 'liver injury' named entity 'infection' named entity 'hypoxia' named entity '95% CI' named entity 'lymphocytes' named entity 'MERS-CoV' named entity 'liver' named entity 'inflammation' named entity 'prognosis' named entity 'hypoxia' named entity 'AST' named entity 'TBIL' named entity 'AST' named entity 'TBIL' named entity 'liver' named entity 'ICU' named entity 'COVID-19' named entity 'liver' named entity 'antiviral agents' named entity 'AST' named entity 'prognosis' named entity 'COVID-19' named entity 'asymptomatic' named entity 'COVID-19' named entity 'D-dimer' named entity 'liver' named entity 'infection' named entity 'AST' named entity 'TBIL' named entity 'statistically significant' named entity 'leukocyte count' named entity 'ischemia' named entity '1.000' named entity 'SARS-CoV-2' named entity 'medical history' named entity 'inflammatory cytokines' named entity 'eosinophils' named entity 'NAFLD' named entity 'AST' named entity 'oxygen' named entity 'virus' named entity 'WBC' named entity 'liver'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software